Effects of palmitoylethanolamide and silymarin combination treatment in an animal model of kidney ischemia and reperfusion

Daniela Impellizzeri, Giuseppe Bruschetta, Akbar Ahmad, Rosalia Crupi, Rosalba Siracusa, Rosanna Di Paola, Irene Paterniti, Marco Prosdocimi, Emanuela Esposito, Salvatore Cuzzocrea

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The aim of this study was to investigate the efficacy of PEA+silymarin as a combination treatment in a mouse model of renal I/R and to verify whether PEA+silymarin could exert more potent effects compared to the single substances even if administered at lower doses. Mice were subjected to bilateral renal artery occlusion (30 min) and reperfusion (6 h) and received intraperitoneally silymarin (100, 30 and 10 mg/kg) or PEA (1 mg/kg) or PEA (1 mg/kg)+silymarin (10 mg/kg) 15 min before release of clamps. Specific indicators of renal dysfunction, tubular injury, myeloperoxidase activity and malondialdehyde levels were measured. The nuclear factor κB pathway and apoptotic mechanisms were also investigated. The treatment with silymarin reduced kidney dysfunction, histological damage, neutrophil infiltration and oxidative stress in a dose dependent manner. Furthermore, PEA+silymarin showed a significant potentiated effect. Therefore, NF-κB and apoptosis pathways were also significantly inhibited. Our results clearly demonstrate that PEA+silymarin treatment attenuated the degree of renal inflammation.

Original languageEnglish (US)
Pages (from-to)136-149
Number of pages14
JournalEuropean Journal of Pharmacology
Volume762
DOIs
StatePublished - Jun 3 2015

Fingerprint

Silymarin
Reperfusion
Ischemia
Animal Models
Kidney
Neutrophil Infiltration
Renal Artery
palmidrol
Malondialdehyde
Peroxidase
Oxidative Stress
Apoptosis
Inflammation
Wounds and Injuries

Keywords

  • Apoptosis
  • Cytokines
  • Inflammation
  • Oxidative stress
  • Renal disease

ASJC Scopus subject areas

  • Pharmacology
  • Medicine(all)

Cite this

Effects of palmitoylethanolamide and silymarin combination treatment in an animal model of kidney ischemia and reperfusion. / Impellizzeri, Daniela; Bruschetta, Giuseppe; Ahmad, Akbar; Crupi, Rosalia; Siracusa, Rosalba; Di Paola, Rosanna; Paterniti, Irene; Prosdocimi, Marco; Esposito, Emanuela; Cuzzocrea, Salvatore.

In: European Journal of Pharmacology, Vol. 762, 03.06.2015, p. 136-149.

Research output: Contribution to journalArticle

Impellizzeri, D, Bruschetta, G, Ahmad, A, Crupi, R, Siracusa, R, Di Paola, R, Paterniti, I, Prosdocimi, M, Esposito, E & Cuzzocrea, S 2015, 'Effects of palmitoylethanolamide and silymarin combination treatment in an animal model of kidney ischemia and reperfusion', European Journal of Pharmacology, vol. 762, pp. 136-149. https://doi.org/10.1016/j.ejphar.2015.05.010
Impellizzeri, Daniela ; Bruschetta, Giuseppe ; Ahmad, Akbar ; Crupi, Rosalia ; Siracusa, Rosalba ; Di Paola, Rosanna ; Paterniti, Irene ; Prosdocimi, Marco ; Esposito, Emanuela ; Cuzzocrea, Salvatore. / Effects of palmitoylethanolamide and silymarin combination treatment in an animal model of kidney ischemia and reperfusion. In: European Journal of Pharmacology. 2015 ; Vol. 762. pp. 136-149.
@article{fdb4f2f936f5499989aa205c09eb3ed9,
title = "Effects of palmitoylethanolamide and silymarin combination treatment in an animal model of kidney ischemia and reperfusion",
abstract = "The aim of this study was to investigate the efficacy of PEA+silymarin as a combination treatment in a mouse model of renal I/R and to verify whether PEA+silymarin could exert more potent effects compared to the single substances even if administered at lower doses. Mice were subjected to bilateral renal artery occlusion (30 min) and reperfusion (6 h) and received intraperitoneally silymarin (100, 30 and 10 mg/kg) or PEA (1 mg/kg) or PEA (1 mg/kg)+silymarin (10 mg/kg) 15 min before release of clamps. Specific indicators of renal dysfunction, tubular injury, myeloperoxidase activity and malondialdehyde levels were measured. The nuclear factor κB pathway and apoptotic mechanisms were also investigated. The treatment with silymarin reduced kidney dysfunction, histological damage, neutrophil infiltration and oxidative stress in a dose dependent manner. Furthermore, PEA+silymarin showed a significant potentiated effect. Therefore, NF-κB and apoptosis pathways were also significantly inhibited. Our results clearly demonstrate that PEA+silymarin treatment attenuated the degree of renal inflammation.",
keywords = "Apoptosis, Cytokines, Inflammation, Oxidative stress, Renal disease",
author = "Daniela Impellizzeri and Giuseppe Bruschetta and Akbar Ahmad and Rosalia Crupi and Rosalba Siracusa and {Di Paola}, Rosanna and Irene Paterniti and Marco Prosdocimi and Emanuela Esposito and Salvatore Cuzzocrea",
year = "2015",
month = "6",
day = "3",
doi = "10.1016/j.ejphar.2015.05.010",
language = "English (US)",
volume = "762",
pages = "136--149",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - Effects of palmitoylethanolamide and silymarin combination treatment in an animal model of kidney ischemia and reperfusion

AU - Impellizzeri, Daniela

AU - Bruschetta, Giuseppe

AU - Ahmad, Akbar

AU - Crupi, Rosalia

AU - Siracusa, Rosalba

AU - Di Paola, Rosanna

AU - Paterniti, Irene

AU - Prosdocimi, Marco

AU - Esposito, Emanuela

AU - Cuzzocrea, Salvatore

PY - 2015/6/3

Y1 - 2015/6/3

N2 - The aim of this study was to investigate the efficacy of PEA+silymarin as a combination treatment in a mouse model of renal I/R and to verify whether PEA+silymarin could exert more potent effects compared to the single substances even if administered at lower doses. Mice were subjected to bilateral renal artery occlusion (30 min) and reperfusion (6 h) and received intraperitoneally silymarin (100, 30 and 10 mg/kg) or PEA (1 mg/kg) or PEA (1 mg/kg)+silymarin (10 mg/kg) 15 min before release of clamps. Specific indicators of renal dysfunction, tubular injury, myeloperoxidase activity and malondialdehyde levels were measured. The nuclear factor κB pathway and apoptotic mechanisms were also investigated. The treatment with silymarin reduced kidney dysfunction, histological damage, neutrophil infiltration and oxidative stress in a dose dependent manner. Furthermore, PEA+silymarin showed a significant potentiated effect. Therefore, NF-κB and apoptosis pathways were also significantly inhibited. Our results clearly demonstrate that PEA+silymarin treatment attenuated the degree of renal inflammation.

AB - The aim of this study was to investigate the efficacy of PEA+silymarin as a combination treatment in a mouse model of renal I/R and to verify whether PEA+silymarin could exert more potent effects compared to the single substances even if administered at lower doses. Mice were subjected to bilateral renal artery occlusion (30 min) and reperfusion (6 h) and received intraperitoneally silymarin (100, 30 and 10 mg/kg) or PEA (1 mg/kg) or PEA (1 mg/kg)+silymarin (10 mg/kg) 15 min before release of clamps. Specific indicators of renal dysfunction, tubular injury, myeloperoxidase activity and malondialdehyde levels were measured. The nuclear factor κB pathway and apoptotic mechanisms were also investigated. The treatment with silymarin reduced kidney dysfunction, histological damage, neutrophil infiltration and oxidative stress in a dose dependent manner. Furthermore, PEA+silymarin showed a significant potentiated effect. Therefore, NF-κB and apoptosis pathways were also significantly inhibited. Our results clearly demonstrate that PEA+silymarin treatment attenuated the degree of renal inflammation.

KW - Apoptosis

KW - Cytokines

KW - Inflammation

KW - Oxidative stress

KW - Renal disease

UR - http://www.scopus.com/inward/record.url?scp=84930686012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930686012&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2015.05.010

DO - 10.1016/j.ejphar.2015.05.010

M3 - Article

C2 - 25981305

AN - SCOPUS:84930686012

VL - 762

SP - 136

EP - 149

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -